TriangleNavDx HPV ctDNA Testing (NCT04900623)
NavDx HPV ctDNA Testing trial for HPV-Associated Oropharyngeal Squamous Cell Carcinoma (NCT04900623). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged twenty-two or older with HPV-associated tongue-base, tonsil, or unknown-primary cancer, stage I–III excluding N3. Detectable HPV16 tumor DNA in blood and planned nonsurgical treatment are required.
The idea: tumor stage, smoking history, and HPV blood tests guide radiation intensity. Lower-risk patients receive reduced radiation over five to six weeks; higher-risk patients receive standard doses over seven to eight weeks. Chemotherapy is selected when appropriate. Researchers measure two-year progression-free survival.
This phase 2 study plans 145 patients. Jonathan Schoenfeld leads at Dana-Farber; two Boston sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.